Roche Holding AG
Suletud
SektorTervishoid
339.2 1.13
Ülevaade
Aktsiahinna muutus
24h
Min
338.2
Max
339.2
Sissetulek | 1.8B 5.5B |
|---|---|
Müük | 15B 31B |
P/E Sektori keskmine | 21.01 49.701 |
Dividenditootlus | 2.98 |
Kasumimarginaal | 17.892 |
Töötajad | 103,249 |
EBITDA | 5.1B 12B |
Dividenditootlus Sektori keskmine | 2.98% 2.39% |
|---|
Turukapital | -21B 268B |
|---|---|
Eelmine avamishind | 338.07 |
Eelmine sulgemishind | 339.2 |
Uudiste sentiment
By Acuity
27%
73%
65 / 345 Pingereas Healthcare
Roche Holding AG Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Roche Holding AG Prognoos
Sentiment
By Acuity
65 / 345 Pingereas Tervishoid
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
